Literature DB >> 29282218

A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance.

Soracha E Ward1, Jamie M O'Sullivan1, Clive Drakeford1, Sonia Aguila1, Christopher N Jondle2, Jyotika Sharma2, Padraic G Fallon3, Teresa M Brophy1, Roger J S Preston1, Paul Smyth4, Orla Sheils4, Alain Chion1, James S O'Donnell1,5.   

Abstract

Previous studies have shown that loss of terminal sialic acid causes enhanced von Willebrand factor (VWF) clearance through the Ashwell-Morrell receptor (AMR). In this study, we investigated (1) the specific importance of N- vs O-linked sialic acid in protecting against VWF clearance and (2) whether additional receptors contribute to the reduced half-life of hyposialylated VWF. α2-3-linked sialic acid accounts for <20% of total sialic acid and is predominantly expressed on VWF O-glycans. Nevertheless, specific digestion with α2-3 neuraminidase (α2-3Neu-VWF) was sufficient to cause markedly enhanced VWF clearance. Interestingly, in vivo clearance experiments in dual VWF-/-/Asgr1-/- mice demonstrated enhanced clearance of α2-3Neu-VWF even in the absence of the AMR. The macrophage galactose-type lectin (MGL) is a C-type lectin that binds to glycoproteins expressing terminal N-acetylgalactosamine or galactose residues. Importantly, the markedly enhanced clearance of hyposialylated VWF in VWF-/-/Asgr1-/- mice was significantly attenuated in the presence of an anti-MGL inhibitory antibody. Furthermore, dose-dependent binding of human VWF to purified recombinant human MGL was confirmed using surface plasmon resonance. Additionally, plasma VWF:Ag levels were significantly elevated in MGL1-/- mice compared with controls. Collectively, these findings identify MGL as a novel macrophage receptor for VWF that significantly contributes to the clearance of both wild-type and hyposialylated VWF.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29282218     DOI: 10.1182/blood-2017-06-787853

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Identification of a secondary binding site in human macrophage galactose-type lectin by microarray studies: Implications for the molecular recognition of its ligands.

Authors:  Filipa Marcelo; Nitin Supekar; Francisco Corzana; Joost C van der Horst; Ilona M Vuist; David Live; Geert-Jan P H Boons; David F Smith; Sandra J van Vliet
Journal:  J Biol Chem       Date:  2018-11-30       Impact factor: 5.157

Review 2.  A review of pig liver xenotransplantation: Current problems and recent progress.

Authors:  Xuan Zhang; Xiao Li; Zhaoxu Yang; Kaishan Tao; Quancheng Wang; Bin Dai; Shibin Qu; Wei Peng; Hong Zhang; David K C Cooper; Kefeng Dou
Journal:  Xenotransplantation       Date:  2019-02-15       Impact factor: 3.907

3.  Glycosylation sterically inhibits platelet adhesion to von Willebrand factor without altering intrinsic conformational dynamics.

Authors:  Alexander Tischer; Venkata R Machha; Laurie Moon-Tasson; Linda M Benson; Matthew Auton
Journal:  J Thromb Haemost       Date:  2019-09-03       Impact factor: 5.824

4.  Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation.

Authors:  Judicael Fazavana; Teresa M Brophy; Alain Chion; Niamh Cooke; Virginie Terraube; Justin Cohen; Chuenlei Parng; Debra Pittman; Orla Cunningham; Matthew Lambert; James S O'Donnell; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

5.  Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the hematologist's view.

Authors:  Margaret V Ragni
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Mechanisms of anti-GPIbα antibody-induced thrombocytopenia in mice.

Authors:  Yosuke Morodomi; Sachiko Kanaji; Eric Won; Zaverio M Ruggeri; Taisuke Kanaji
Journal:  Blood       Date:  2020-06-18       Impact factor: 22.113

Review 7.  Genetic regulation of plasma von Willebrand factor levels in health and disease.

Authors:  L L Swystun; D Lillicrap
Journal:  J Thromb Haemost       Date:  2018-10-30       Impact factor: 5.824

Review 8.  Low VWF: insights into pathogenesis, diagnosis, and clinical management.

Authors:  James S O'Donnell
Journal:  Blood Adv       Date:  2020-07-14

Review 9.  Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?

Authors:  Dafna J Groeneveld; Lauren G Poole; James P Luyendyk
Journal:  J Thromb Haemost       Date:  2021-05-03       Impact factor: 16.036

Review 10.  The relationship between ABO blood group, von Willebrand factor, and primary hemostasis.

Authors:  Soracha E Ward; Jamie M O'Sullivan; James S O'Donnell
Journal:  Blood       Date:  2020-12-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.